Krka, d. d.
KRK
Rank in Stocks
#2128
Krka, d. d. is a leading generic pharmaceutical enterprise primarily involved... Krka, d. d. is a leading generic pharmaceutical enterprise primarily involved in the research, production, promotion, and sale of various pharmaceutical goods. Its market presence spans Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and numerous other international territories. The company's offerings are categorized into prescription medications, over-the-counter products, and veterinary health solutions. Its prescription drug pipeline targets a broad spectrum of medical conditions, including cardiovascular disorders, gastrointestinal issues, central nervous system ailments, pain management, anti-infective treatments, conditions affecting blood and blood-forming organs, urological problems, diabetes, and oncology. The array of non-prescription items includes products for oral and throat care, cough and cold remedies, analgesics, nasal preparations, vitamin and mineral supplements, products designed to enhance cerebral and peripheral circulation, digestive aids, and various general healthcare products. Furthermore, Krka supplies animal health products such as anti-infectives, antiparasitics, and other specialized formulations for both livestock and companion animals. Beyond its pharmaceutical operations, the company also provides health resort and tourist services. Krka, d. d. was established in 1954 and has its corporate headquarters in Novo Mesto, Slovenia.
Share Price
$318.12
Market Cap
$9.63B
Change (1 day)
0.18%
Change (1 year)
32.75%
Country
SI
Trade Krka, d. d. (KRK)
Category
Healthcare
P/E ratio for Krka, d. d. (KRK)
P/E ratio as of October 2026 TTM: 19.17
According to Krka, d. d. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 19.17. At the end of 2023 the company had a P/E ratio of 10.10.
P/E ratio history for Krka, d. d. from 2010 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 19.17 | 62.47% |
| 2024 | 11.80 | 16.87% |
| 2023 | 10.10 | 27.23% |
| 2022 | 7.94 | -34.24% |
| 2021 | 12.07 | 18.94% |
| 2020 | 10.15 | 8.51% |
| 2019 | 9.35 | -10.98% |
| 2018 | 10.51 | -11.02% |
| 2017 | 11.81 | -29.73% |
| 2016 | 16.80 | 23.10% |
| 2015 | 13.65 | 21.03% |
| 2014 | 11.28 | -1.67% |
| 2013 | 11.47 | 2.33% |
| 2012 | 11.21 | 15.69% |
| 2011 | 9.69 | -7.58% |
| 2010 | 10.48 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | 82.35% |
IN
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.